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Abstract 
Introduction: Heart failure (HF) patients are at high-risk of cardiovascular (CV) events, including CV 
death. Nonetheless, a substantial proportion of these patients die from non-CV causes. Identifying 
patients at higher risk for each individual event may help selecting patients for clinical trials and 
tailoring cardiovascular therapies.   
Aims: The aims of the present study are to: 1) characterize the patients according to CV vs. non-CV 
death; 2) develop models for the prediction of the respective events; 3) assess the models` 
performance to differentiate CV from non-CV death. 
Methods: This study included 2,309 patients with HF from the BIOSTAT-CHF (A systems BIOlogy 
Study to TAilored Treatment in Chronic Heart Failure) study. Competing-risk models were used to 
assess the best combination of variables associated with each cause-specific death. Results were 
validated in an independent cohort of 1,738 HF patients. 
Results: The best model to predict CV death included low blood pressure, eGFR≤60 ml/min, 
peripheral edema, previous HF hospitalization, ischemic HF, COPD, elevated NT-proBNP, and 
troponin (c-index=0.73). The non-CV death model incorporated age>75y, anemia and elevated NT-
proBNP (c-index=0.71). Both CV and non-CV death rose by quintiles of the risk scores; yet these 
models allowed the identification of patients in whom the absolute CV death rates clearly outweigh 
the non-CV death ones. These findings were externally replicated, but performed worse in a less-
severely diseased population.  
Conclusions: Risk models for predicting CV and non-CV death allowed the identification of patients 
at higher absolute risk of dying from CV causes (vs. non-CV ones). Troponin helped in predicting CV 
death only, whereas NT-proBNP helped in the prediction of both CV and non-CV death. These 
findings can be useful both for tailoring therapies and for patient selection in HF trials in order to 
attain CV event enrichment. 
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Heart failure (HF) patients are at high risk of cardiovascular (CV) events, including CV death1, 2. 
Nonetheless, a substantial proportion of patients die from non-CV causes (e.g., infection, cancer, 
multiorgan failure)3. In HF trials, a composite of CV death or HF hospitalization is generally used. 
Identifying  patients at higher risk for each mode of death (CV vs. non-CV) may help in tailoring 
specific therapies, developing prevention strategies, providing information to patients and their 
families, and also in selecting patients for clinical trials (those at higher risk for CV death, may 
experience more benefit from CV drugs)4.   
 Patients` clinical information (medical history, signs and symptoms), plus a few parameters 
routinely available in clinical practice (blood pressure, heart rate, electrocardiography, 
echocardiography, and laboratory results such as hemoglobin and renal function) may provide useful, 
precise and highly discriminatory information with regards to patients` outcome5, 6. However, 
determining if an individual-patient is at higher risk of dying from CV or non-CV causes may be more 
challenging7. Natriuretic peptides (e.g. NT-pro BNP) are strong prognosticators in HF and, 
consequently, are often used as an “enrichment” criterion in HF trials8, 9. However, patients with high 
natriuretic peptides (NPs) may be at an increased risk for both CV and non-CV death, which may be 
problematic when testing CV drugs due to the high proportion of competing non-CV events. 
Therefore, the ability to determine patients` risk for a specific mode of death using clinical data, NPs, 
and troponin (variables routinely available both in clinical practice and research) may be of high 
relevance to tailor HF treatments and also for clinical trials, where treating high CV-risk (and ideally 
low non-CV risk) patients is desirable.  
 In BIOSTAT-CHF (A systems BIOlogy Study to TAilored Treatment in Chronic Heart 
Failure) the events were adjudicated and the causes of death (CV vs. non-CV) could be determined. 
Moreover, clinical parameters are detailed and NT-pro BNP plus Troponin T were determined with 
up-to-date technology.  
The aims of the present study are to: 1) characterize the patients according to CV vs. non-CV 
death; 2) develop models with good discrimination for the prediction of the respective events; 3) 
assess the performance of the models to identify and differentiate CV from non-CV death.  
 
Methods 
Patient population  
BIOSTAT-CHF is a European project that enrolled 2,516 patients with worsening HF on less than 
guideline-recommended doses of medication from 69 centres in 11 European countries to 
investigate the factors predicting the response to attempted up-titration of HF therapies. The design 
and first results of the study and patients have been published10. Briefly, patients were aged ≥18 years 
with signs and symptoms of worsening HF managed either in an out-patient clinic or hospital ward. 
The diagnosis of HF was confirmed either by a left ventricular ejection fraction (LVEF) of ≤40% or a 
BNP and/or NT-proBNP plasma levels >400 pg/mL and/or >2000 pg/mL, respectively. Patients 
needed to be treated with either oral or intravenous furosemide ≥40 mg/day or equivalent at the time 
of inclusion. Patients were either treatment naïve with respect to disease-modifying therapies 
(ACEi/ARBs and beta-blockers) or were receiving <50% of the target doses of at least one of these 
drugs at the time of inclusion11, 12.  
The recruitment period lasted 24 months, starting from December 2010. The last patient was 
included on December 15, 2012.  
The median (pct25-75) follow-up time was 21 (9-26) months.  
Study outcomes 
The primary outcome was a composite of heart failure hospitalization (HFH) and all-cause mortality 
(ACM). The adjudication of HFH was performed by the treating physician. After the trial had ended 
all medical reports of the mortality events were read and adjudicated by Adriaan A. Voors based on 
the (medical registries from the case record forms) and the cause of death (CV or non-CV death) was 
ascertained and inserted in the dataset. The criteria used for the event adjudication are shown in the 
supplemental material (table 8).  
Ethics Board approval was obtained and all participants signed written informed consent 
before entering the study.  
Validation cohort 
The findings presented herein were also externally validated. The BIOSTAT-CHF validation cohort 
was designed as a multicentre, prospective, observational study. The study population consisted of 
1,738 patients from six centres in Scotland, UK. The recruitment period started in October 2010 and 
was completed in April 2014. Median follow-up was 21 months. Patients from the validation cohort 
were aged >18 years with a HF diagnosis based on echocardiographic evidence of left ventricular 
dysfunction or a previous documented admission with HF treated with furosemide ≥20 mg/day or 
equivalent, not previously treated or receiving ≤50% of target doses of ACE inhibitors/ARBs and/or 
beta-blockers according to the 2008 European Society of Cardiology guidelines. Patients could be 
enrolled as inpatients or from outpatient clinics10.  
Statistical analysis, biomarker determination, and bioinformatical approach 
Population description and comparison of the patients` characteristics by the occurrence (or not) of 
events was performed using parametric or non-parametric tests, as appropriate.  
Competing-risk models, as described by Fine and Gray13, were used to build the prognostic 
models for CV death (with non-CV death as “competing risk”), non-CV death (with CV death as 
“competing risk”), and hospitalizations (using all-cause death as “competing risk”). The covariates 
used for model development were chosen from demographic (age and sex), clinical (previous HF 
hospitalization, NYHA class, concomitant HF treatments, co-morbidities, body mass index, heart rate, 
blood pressure, and left ventricular ejection fraction), and laboratory (NT-pro BNP, troponin, 
hemoglobin, glomerular filtration rate estimated by the CKD-EPI formula14, 15, and sodium) by their 
well-established prognostic value in HF16 and low proportion of missing values in this cohort. 
Continuous variables were categorized based on clinically relevant cutoffs to build a prognostic model 
ready for clinical application.  
NT-pro BNP and Troponin T-high sensitive (hsTnT) were determined in a central laboratory 
using Roche Elecsys® cobas analyzer; 87% of the patients had hsTnT levels above the 99th percentile 
of 0.14 ng/mL (14 ng/dL).  
The collection of the clinical, biological and biomarker data presented in this analysis was 
performed at baseline i.e. in the first study visit. With the exception of NT-pro BNP and hsTnT 
(analysed centrally) all the other variables were collected and/or analysed in the local laboratories of 
the respective participating centers. Blood pressure was determined with a calibrated 
sphygmomanometer in the sitting position after 5 minutes of rest and taking the mean of three 
measures.    
Variables with >20% of missing values were not included in the models and missing values 
were kept to a minimum (analyses using multiple imputation with chained equations (“MICE”) across 
10 datasets were also performed with overlapping results). A stepwise (backward) procedure was 
applied to each model with p-value set at 0.05 for a variable to stay in the model. We repeated these 
procedures using 1000x bootstrap samples and using Cox regression models (to be concordant with 
the underlying event rate) providing similar estimates to those presented.  
The risk scores were then computed by attributing integer numbers based on the β coefficients 
of the associations, and subsequently divided in quintiles17. We merged both risk scores in a 
“combined risk” score that incorporates  both the variables that predict CV events and also those that 
predict non-CV events; as NT-pro BNP was the only variable that predicted both event types we 
assigned it the weight given in the CV death prediction model (assigning the weight of the non-CV 
death models provided similar estimates). Event-rates, the respective differences and ratios were 
calculated. The “number needed to enroll” (NNE) for a cardiovascular event to occur was also 
calculated by computing the inverse of the absolute difference between cardiovascular and non-
cardiovascular events (analogous to the number needed to treat).  Prespecified interactions between 
hsTnT and HF etiology (ischemic vs. non-ischemic), hsTnT and NT-pro BNP with LVEF (≤40% vs. 
>40%) were tested.  
Exploratory unsupervised Classification and Regression Tree (CART) analysis were also 
computed using failure time data and chi-square values for all possible cut-points on the CART 
covariates.  
All the analyses were performed using STATA (StataCorp. 2015. Stata Statistical Software: 




Patients who died from CV causes had more often HF of ischemic etiology, previous HFH, and lower 
blood pressure. Those who died from non-CV causes were older, had more often a LVEF >40%, 
anemia, atrial fibrillation, history of cancer, and an eGFR ≤60 ml/min. Table 1. Patients` 
characteristics adding the mode of hospitalization in those who remained alive during the follow-up is 
presented in the Supplemental Table 1. A total of 657 patients died during the follow-up; of these 
441 (67.1%) died from CV causes and 216 (32.9%) from non-CV causes.  
Competing-risk clinical models for the specific events 
The point-score model to predict CV death included systolic blood pressure (SBP) <110 mmHg, 
presence of peripheral edema, HF of ischemic etiology, chronic obstructive pulmonary disease 
(COPD), eGFR ≤60 ml/min, NT-pro BNP, and hsTnT categories. The model presented good 
discrimination (c-index =0.73). The model to predict non-CV death included age above 75 years, 
anemia, and NT-pro BNP categories. This model also presented a good discrimination (c-index 
=0.71). Table 2. The same model with using continuous variables presented the same discriminatory 
capacity and is presented in the Supplemental Table 2.    
No statistical interactions were found between the etiology of HF (ischemic or non-ischemic) 
and the predictive value of hsTnT (p for interaction =0.34), LVEF (≤40% vs. >40%) and the 
predictive value of troponin (p for interaction =0.26) or NT-pro BNP (p for interaction =0.80). 
Competing risk models to predict hospitalizations (HF and non-HF) were also developed 
(presented in the Supplemental Table 3). Independent predictors of HF hospitalization included 
NYHA III or IV, previous HF hospitalization, diabetes, active smoking, eGFR ≤60 ml/min, and 
elevated NT-pro BNP; with moderate discrimination (c-index =0.68). The model for predicting non-
HF hospitalization performed poorly (c-index =0.56), and these patients had much lower risk 
compared with those hospitalized for HF. Supplemental Figure 1.   
Risk differentiation between CV and non-CV death 
A steep increase in the CV and non-CV death rates was observed by quintiles of the respective risk 
scores (Table 3), with good calibration (Supplemental Figure 2).   
 For example, patients with ≥6 points (i.e. quintile ≥3) in the CV death risk score had >16% 
CV death events during the follow-up, corresponding to >7 events per 100py. Patients in the top 
quintile of the CV death risk score (≥10 points) had >44% events during the follow-up, corresponding 
to >32 events per 100py. Table 3 & Figure 1. The absolute event rate difference (CV minus non-CV 
death) for patients with ≥6 points in the CV death risk score is ≥5 events per 100py, up to 25 events 
per 100py in patients with ≥10 points (i.e. “top” quintile of the CV death risk score); consequently, 
the number of patients needed to enrol (NNE) to have a CV death event (over a non-CV death one) 
decreases steeply by quintiles of the CV risk score, and is of 20 patients in those with a risk score of 6 
or 7, 12 patients if the score is 8 or 9, and 4 patients if the score is 10 or greater. Table 3. Below a CV 
risk score of 6 (i.e. quintiles 1 and 2) the CV death event rates are much lower (9% during the follow-
up; <7 events per 100py) and not that different from the non-CV death ones (event rate difference <2 
events per 100py). Table 3 & Figure 1.  
The CV-death risk model was also well calibrated for non-CV death i.e. non-CV death event 
rates increase steeply per each quintile of the CV death risk score; suggesting that when the CV-death 
risk is enhanced, the non-CV death risk also rises. Consequently, the CV to non-CV death ratio does 
not illustrate the potential difference between these two event “types”, but the absolute difference 
does. Table 3 (see also the discussion section).   
NT-pro BNP was associated with both CV death and non-CV death; although NT-pro BNP 
had a stronger association (i.e. “weight”) for predicting CV death compared with non-CV death (β 
estimates for NT-pro BNP between 1500 and 5000 are of 0.52 for CV death and 0.44 for non-CV 
death; and of 0.84 and 0.62 NT-pro BNP above 5000, respectively). Troponin was an independent 
predictor of CV-death but not of non-CV death. These findings were also supported by unsupervised 
CART analyses, depicted in the Supplemental Figure 3, where troponin was selected as the top 
discriminator for CV death but was not considered by the model to classify non-CV death.  
Combining the CV and non-CV death risk scores (Table 3) allows the computation and 
comparison of these scenarios for each individual patient in a “real-world” scenario i.e. for risk 
assessment and/or for CV risk enrichment in clinical trials. For this purpose, an Online Calculator is 
available. The CV vs. non-CV death event rate comparison is visually depicted in the Figure 2. 
 We also analysed the patients at high risk for CV death (≥6 points in the CV death risk score) 
and low risk for non-CV death (≤2 points in the non-CV death risk score). Patients with a high risk of 
CV death and low risk of non-CV death represented 21% of the BIOSTAT-CHF study population, 
whereas patients with a low risk of CV death and high-risk of non-CV death represented 5% of the 
study population (Table 4). Patients with high risk of CV death and low risk of non-CV death have 
higher levels of NT-pro BNP and hsTnT, and CV death event rates when compared with the other 
remaining patients. Supplemental Table 4 & 5.  
External validation 
The findings were replicated but performed worse in the validation cohort. With exception of the 
quintile 2 where few patients/events were present (n =99 for CV death and n =78 for non-CV death); 
higher event rates were also observed per incremental quintiles of risk in the validation cohort. 
However, the event rates were overall lower in the validation cohort because this population had less 
severe HF. Moreover, the validation cohort has a smaller sample size than the derivation one (n=1,738 
vs. n =2,309). 
 The results for the individual components on the risk score for both CV death and non-CV 
death are presented in the Supplemental Table 6. The c-index of the model for CV death is 0.66 and 
for non-CV death 0.60.  
Patients with 7 or more points in the combined risk score had an “excess” of CV death events 
(over non-CV death i.e. ratio >1) with a steep increase in the event rate difference (and consequently 
lower “number needed to enrol”) in favour of CV death. Supplemental Table 7.  
 
Discussion 
To our knowledge, this is the first study to show that a distinction between patients at high risk for CV 
death and non-CV death is possible using a set of routinely available clinical and biochemical 
variables. The “risk scores” here developed may be used in clinical practice for identifying patients at 
high risk for CV death, and for clinical trials were a CV over non-CV death enrichment is required to 
test the efficacy of CV drugs while decreasing the odds for competing non-CV events.  
 Predicting the occurrence of events throughout the follow-up using models that incorporated 
biomarkers has been attempted in patients with atrial fibrillation enrolled in the ARISTOTLE trial18. 
In this analysis hsTnT and NT-pro BNP were strongly associated with CV death; however, non-CV 
death was not assessed and whether these biomarkers could differentiate the modes of death was not 
determined. A study including 4842 patients hospitalized for acute HF assessed the factors associated 
with non-CV death19. Over a median follow-up of 17 months 1183 patients died, of whom 356 (30%) 
from non-CV causes. The proportion of non-CV death events was similar to that found in our cohort, 
and age and low hemoglobin were also independently associated with this mode of death19. 
Notwithstanding, this study did not assess CV death, biomarkers, nor the capacity of clinical variables 
to identify different modes of death. Serial hsTnT measurements were also performed in the RELAX-
AHF study and found to be strongly associated with adverse cardiovascular outcomes, particularly 
CV death at 180 days20; but the potential capacity of hsTnT for differentiating the modes of death was 
also not assessed. Other reports that studied the association of biomarkers with different modes of 
death also did not ascertain the capacity of these biomarkers (on top of the clinical variables) to 
differentiate CV from non-CV death21.  
The present study goes beyond the previous published reports. We developed two calibrated 
(and easy to compute) risk models able to identify patients at high risk for CV death and also assess 
which patients will likely have high CV to non-CV death rates difference, potentially benefiting more 
from CV drugs while less prone to non-CV competing events.  
A few examples may illustrate the potential use of these models. Patients with ≥6 points in the 
CV death risk score have high CV death event rates during follow up (>16%; >7 events per 100py) 
with a non-CV death difference of more than 5 events per 100py. Even considering the patients at 
higher risk for non-CV death events (i.e. those in the top quintile of the non-CV death score) versus 
those with intermediate risk for CV death (i.e. third quintile or 6-7 points in the CV death score), they 
have at least similar CV to non-CV death event rates. In this regard, the combined (CV and non-CV 
death) risk score available as Online Calculator (and also visualized in the Figure 2) allows the 
computation of these scenarios in a “real-world” setting. In a “practical” example for a hypothetical 
HF trial, enrolling patients with signs and symptoms of HF, elevated NT-pro BNP and detectable 
troponin (while “capping” the enrolment of very old patients and those with anemia) may “enrich” the 
CV death rates and increase the CV to non-CV death absolute difference i.e. decreases the overall 
probability on non-CV competing risks. As non-CV death events also increase along with  the CV-
death ones, looking at the absolute even-rate differences is more informative than the “ratio”, as the 
event-rate difference increases steeply by each quintile of the combined risk score, whereas the ratio 
does not (e.g., in patients with ≥7 points in the combined risk score Online Calculator the event rate 
difference increases from 4.2 events per 100py in those with 7 or 8 points, to 16.6 events per 100py in 
those with 11 to 16 points, whereas the event ratio remains around 2).  
In addition to the clinical features, the association of hsTnT with CV death (but not with non-
CV death) adds additional differentiation, and should be incorporated when assessing the risk of CV 
death in HF patients, as even small elevations in hsTnT are associated with increased CV event 
rates22. This observation may be explained by the fact that troponin is cardiac-specific and is 
detectable in many HF patients even in the absence of clinically apparent myocardial ischemia22. It 
should be emphasized that we did not find heterogeneity (“statistical interaction”) between the HF 
etiology (ischemic vs. non-ischemic) and the predictive value of troponin, supporting the use of 
troponins for CV death risk assessment also in patients without ischemic HF. On the other hand, NT-
pro BNP elevations may be found in association with older age, impaired renal function, infections, 
cancer, atrial fibrillation and many other cardiac and non-cardiac condition, that preclude this 
biomarker from differentiating the risk of CV vs. non-CV death23, 24. For example, a patient with a 
hsTnT of 0.06 ng/mL and a NT-pro BNP of 2000 pg/mL already counts “6 points” in the combined 
score (regardless of the other variables); this individual patient will be at higher risk for CV death 
(relative to non-CV death) because only patients with NT-pro BNP above 5000 pg/mL, aged above 75 
and with anemia would be at similar risk for CV and non-CV death, but unlikely at higher risk. 
The model built for identifying patients at higher risk for HF hospitalization, retained 
variables associated with HF severity, eGFR ≤60 ml/min, diabetes, current smoking and NT-pro BNP 
but not troponin; suggesting that HF hospitalizations may be driven by several causes beyond the 
“disease progression” (e.g. infections, arrhythmias, renal dysfunction, drug intolerance, etc) and that 
adjudication of these events may be very challenging. For example, in our study patients identified as 
admitted for non-HF causes had a very low event risk, suggesting that these patients were probably 
admitted for “programmed” procedures. Either way, HF hospitalizations were associated with high 
overall subsequent death rates (CV and non-CV) and a careful event adjudication is warranted when 
considering time-to-first composite end points in HF trials.     
These findings may have a high impact both for current clinical practice and HF trials. 
Identifying patients at higher risk for CV death may help in tailoring CV therapies (e.g. drug up-
titration, coronary ischemia test or device implant) and in selecting patients for future HF trials, where 
the tested drugs are targeted at reducing the CV death events, specifically.  
Limitations 
Several limitations should be acknowledged in this analysis. First, the data from the BIOSTAT-CHF 
come from European centres only and may not be representative of HF patients in other world 
regions. Second, all patients enrolled in the BIOSTAT-CHF had severe symptoms and high natriuretic 
peptide levels, hence these findings cannot be generalized to less symptomatic HF patients. Third, 
patients enrolled herein were included if they had suboptimal HF treatment, which can also limit the 
generalization of our results to HF patients with optimized medical treatment. However, the medical 
treatment in BIOSTAT-CHF was similar to other registries and doctors were instructed to up-titrate 
treatment during follow-up. Fourth, CV death was adjudicated directly from the clinical record forms 
and the subspecific modes of death (e.g. sudden, sepsis) are not available in the dataset. Fifth, HF 
hospitalizations were adjudicated by the investigators at the site-level and may be prone to 
adjudication bias. Sixth, patients with active malignancies and with infection/sepsis as the cause of 
admission were excluded from the BIOSTAT-CHF study, these are important variables that may 
account for high non-CV death risk a “real-world” setting. Seventh, the external validation cohort 
consisted of a smaller sample of patients with less severe HF, which may have compromised the 
external performance of the models.  
 
Conclusion 
Risk models for predicting CV and non-CV death allowed the identification of patients at higher 
absolute risk of dying from CV causes (vs. non-CV ones). Troponin helped in predicting CV death 
only, whereas NT-proBNP helped in the prediction of both CV and non-CV death. In addition to 
clinical features and NT-pro BNP, troponin should be considered to identify HF patients at high CV-
death risk, both for tailoring therapies and for patient selection in future HF trials. 
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Table 1. Characteristics of the BIOSTAT-CHF population according to the studied events 
Patients` characteristics Alive CV death Non-CV death p-value % MV 
N. 1859 441 216 
 
 
Age, years 67.1 ± 11.9 71.7 ± 11.2 73.3 ± 10.9 <0.001 0 
Male 1370 (73.7%) 325 (73.7%) 151 (69.9%) 0.48 0 
BMI, kg/m2 28.1 ± 5.5 27.3 ± 5.49 27.2 ± 5.5 0.006 2% 
Heart rate, bpm 82 ± 22 82 ± 20 82 ± 22 0.90 1% 
SBP, mmHg 126 ± 22 121 ± 22 124 ± 24 <0.001 0 
Pulm. congestion/Rales 892 (49.4%) 264 (61.8%) 135 (63.7%) <0.001 3% 
Peripheral edema 839 (54.8%) 281 (73.6%) 136 (72.7%) <0.001 17% 
Orthopnea 599 (32.3%) 189 (43.1%) 91 (42.3%) <0.001 0 
NYHA III or IV 1049 (58.0%) 315 (73.9%) 158 (75.2%) <0.001 3% 
LVEF (%)  30.70 ± 9.84 30.94 ± 12.11 34.04 ± 13.12 <0.001 11% 
LVEF >40% 142 (7.6%) 51 (11.6%) 42 (19.4%) <0.001 - 
Ischemic HF 771 (41.5%) 231 (52.4%) 101 (46.8%) <0.001 0 
Previous HF hosp. 531 (28.6%) 187 (42.4%) 76 (35.2%) <0.001 0 
PCI/CABG 579 (31.1%) 174 (39.5%) 89 (41.2%) <0.001 0 
Atrial fibrillation 795 (42.8%) 230 (52.2%) 118 (54.6%) <0.001 0 
Stroke 152 (8.2%) 58 (13.2%) 23 (10.6%) 0.004 0 
Peripheral arterial disease 178 (9.6%) 68 (15.4%) 27 (12.5%) 0.001 0 
Device therapy 404 (21.7%) 149 (33.8%) 65 (30.1%) <0.001 0 
Hypertension 1154 (62.1%) 275 (62.4%) 140 (64.8%) 0.73 0 
Diabetes 577 (31.0%) 162 (36.7%) 80 (37.0%) 0.024 0 
Smoking 274 (14.7%) 47 (10.7%) 32 (14.9%) 0.26 0 
COPD 279 (15.0%) 109 (24.7%) 48 (22.2%) <0.001 0 
Current malignancy 60 (3.2%) 20 (4.5%) 17 (7.9%) 0.003 0 
Hemoglobin, g/dL 13.4 ± 1.8 12.7 ± 1.9 12.3 ± 2.2 <0.001 9% 
Anemia 378 (20.3%) 147 (33.3%) 92 (42.6%) <0.001 - 
eGFR, ml/min 65.7 ± 22.4 52.7 ± 23.8 54.1 ± 21.1 <0.001 0 
eGFR <60 775 (41.7%) 286 (64.9%) 144 (66.7%) <0.001 0 
Sodium, mmol/L 139.4 ± 3.7 138.2 ± 4.6 139 ± 4.5 <0.001 8% 
Potassium, mmol/L 4.3 ± 0.5 4.3 ± 0.6 4.3 ± 0.6 0.77 8% 
Glucose, mmol/L 7.1 ± 3.0 7.4 ± 3.3 7.4 ± 3.2 0.11 25% 
NTproBNP, pg/mL 2209 (984, 4777) 4515 (2419, 10138) 4022 (1953, 7486) <0.001 9% 
Troponin T, ng/mL 0.27 (0.17, 0.46) 0.48 (0.31, 0.80) 0.42 (0.27-0.79) <0.001 7% 
Beta-blocker 1578 (84.9%) 349 (79.1%) 166 (76.9%) <0.001 0 
ACE/ARB 1378 (74.1%) 294 (66.7%) 148 (68.5%) 0.003 0 
MRA 1017 (54.7%) 227 (51.5%) 95 (44.0%) 0.008 0 
Legend:  CV, cardiovascular; HF, heart failure; BMI, body mass index; SBP, systolic blood pressure; 
NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; PCI/CABG, 
percutaneous coronary intervention/coronary artery bypass grafting; COPD, chronic obstructive 
pulmonary disease; eGFR, estimated glomerular filtration rate; ACE/ARB, angiotensin converting 
enzyme/angiotensin receptor blockers; MRA, mineralocorticoid receptor antagonists; MV, missing 
values. 
The p-value represents any difference between the categories.
Table 2. Competing-risk clinical models for the specific fatal events 
“Best” predictors SHR (95%CI) Coef. p-value Points 
CV death 
SBP <110 mmHg 1.28 (1.03-1.59) 0.25 0.027 +1 
Per. edema 1.46 (1.14-1.86) 0.38 0.002 +1 
Ischemic HF 1.35 (1.08-1.67) 0.30 0.007 +1 
Previous HF hosp. 1.38 (1.11-1.72) 0.32 0.004 +1 
COPD 1.47 (1.16-1.87) 0.39 0.002 +1 
eGFR ≤60 ml/min 1.27 (1.01-1.59) 0.24 0.045 +1 
NT-proBNP ≤1500, pg/mL Reference - - - 
>1500 & ≤5000 1.69 (1.21-2.35) 0.52 0.002 +2 
>5000 2.31 (1.66-3.22) 0.84 <0.001 +3 
Troponin T ≤0.20, ng/mL Reference - - - 
>0.20 & ≤0.50 1.76 (1.19-2.61) 0.57 0.004 +2 
>0.50 2.98 (2.01-4.42) 1.09 <0.001 +4 
Non-CV death 
Age >75y 2.05 (1.33-3.17) 0.72 0.001 +2 
Anemia 1.88 (1.40-2.53) 0.63 <0.001 +2 
NT-proBNP ≤1500, pg/mL Reference - - - 
>1500 & ≤5000 1.55 (1.04-2.32) 0.44 0.031 +1 
>5000 1.86 (1.23-2.82) 0.62 0.003 +2 
Legend: HF, heart failure; CV, cardiovascular; SBP, systolic blood pressure; eGFR, estimated 
glomerular filtration rate; 
C-index: CV death =0.73; Non-CV death =0.71. 















Table 3. Risk differentiation between CV and non-CV death 
CV death Risk Score (Quintiles) 
Points (from 0 to 13) Total n. CV death n. (%) CV death Inc. Rate Non-CV death n. (%) Non-CV death Inc. Rate Ratio %  Diff. NNE 
0-3 429 28 (6.5) 3.5 (2.4-5.1) 14 (3.3) 1.8 (1.0-2.9) 1.9 1.7 59 
4-5 366 33 (9.0) 4.8 (3.4-6.8) 20 (5.5) 2.9 (1.9-4.5) 1.7 1.9 53 
6-7 440 71 (16.1) 9.0 (7.1-11.4) 39 (8.9) 4.9 (3.6-6.8) 1.8 5.1 20 
8-9 431 112 (26.0) 17.0 (14.1-20.4) 59 (13.7) 8.9 (6.9-11.6) 1.9 8.1 12 
10-13 236 105 (44.5) 39.0 (32.2-47.3) 38 (16.1) 14.1 (10.3-19.4) 2.8 24.9 4 
Non-CV death Risk Score (Quintiles) 
Points (from 0 to 6) Total n. CV death n. (%) CV death Inc. Rate Non-CV death n. (%) Non-CV death Inc. Rate Ratio % Diff. NNE 
0 503 33 (6.6) 3.4 (2.4-4.8) 14 (2.8) 1.4 (0.9-2.4) 2.4 2.0 50 
1 482 65 (13.5) 7.4 (5.8-9.4) 31 (6.4) 3.5 (2.5-5.0) 2.1 3.9 26 
2 456 83 (18.2) 11.2 (9.0-13.8) 37 (8.1) 5.0 (3.6-6.9) 2.2 6.2 16 
3-4 645 155 (24.0) 15.3 (13.1-17.9) 75 (11.6) 7.4 (5.9-9.3) 2.1 7.9 13 
5-6 208 65 (31.2) 21.7 (17.0-27.7) 40 (19.2) 13.4 (9.8-18.2) 1.6 8.3 12 
Combined Risk Score (Quintiles) 
Points (from 0 to 15) Total n. CV death n. (%) CV death Inc. Rate Non-CV death n. (%) Non-CV death Inc. Rate Ratio % Diff. NNE 
0-4 477 30 (6.3) 3.4 (2.3-4.8) 13 (2.7) 1.4 (0.8-2.5) 2.3 2.0 50 
5-6 321 34 (10.5) 5.7 (4.0-7.9) 14 (4.4) 2.3 (1.4-3.9) 2.4 3.4 29 
7-8 401 64 (15.9) 9.0 (7.1-11.5) 34 (8.5) 4.8 (3.4-6.7) 1.9 4.2 24 
9-10 337 79 (23.4) 15.2 (12.2-19.0) 46 (13.7) 8.9 (6.7-11.9) 1.7 6.3 16 
11-16 366 142 (38.8) 29.9 (25.4-35.3) 63 (17.2) 13.3 (10.4-17.0) 2.3 16.6 6 
Legend: CV, cardiovascular; Inc. Rate, incidence rate per 100 person-years; Ratio %, incidence rate ratio; Diff., incidence rate difference; NNE, number 
needed to enrol to have a cardiovascular death event (over a non-cardiovascular one). 
Spearman correlation between the CV and non-CV death scores =0.61.
Table 4. Cross-tabulation of cardiovascular (CV) vs. Non-CV death 
Mode of death / 
Risk score points 
Non-CV death 






 0-3 289 44 66 29 1 
4-5 87 115 63 91 10 
6-7 35 133 90 141 41 
8-9 5 86 97 173 70 
10-13 0 13 61 108 54 
Green: patients with a high CV death risk and low non-CV death risk (n =520; 21%).  
Yellow: patients with a high non-CV death risk and low CV death risk (n=131; 5.2%). 
Figure 1. CV death vs. Non-CV death event rates comparison by quintiles of the respective risk scores 
 
 
Legend: CV, cardiovascular. 
Patients with ≥6 points in the CV death risk score have similar or greater CV death event rates than 


























Figure 2. Cardiovascular and Non-Cardiovascular death event rates per 100py by the quintiles of the 
combined risk score 
 
 
Legend: CV, cardiovascular. 
Note: see also the Table 3.
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Supplemental Table 1. Characteristics of the BIOSTAT-CHF population according to the studied events, including hospitalizations 
Patients` characteristics  No event HF hosp. Non-HF hosp. CV death Non-CV death p-value 
N. 965 360 534 441 216  
Age, years 66.32 ± 12.33 69.91 ± 11.19 66.45 ± 11.49 71.68 ± 11.24 73.26 ± 10.89 <0.001 
Male 687 (71.2%) 269 (74.7%) 414 (77.5%) 325 (73.7%) 151 (69.9%) 0.068 
BMI, kg/m2 28.10 ± 5.39 27.81 ± 5.45 28.29 ± 5.65 27.30 ± 5.49 27.25 ± 5.59 0.017 
Heart rate, bpm 82.07 ± 21.66 81.74 ± 19.64 83.51 ± 23.13 82.00 ± 19.69 81.92 ± 21.81 0.70 
SBP, mmHg 126.74 ± 20.67 123.28 ± 23.79 125.79 ± 21.32 120.68 ± 21.98 123.65 ± 24.02 <0.001 
Pulm. congestion/Rales 454 (48.5%) 200 (57.6%) 238 (45.5%) 264 (61.8%) 135 (63.7%) <0.001 
Peripheral edema 408 (52.0%) 201 (64.6%) 230 (52.9%) 281 (73.6%) 136 (72.7%) <0.001 
Orthopnea 283 (29.3%) 144 (40.0%) 172 (32.3%) 189 (43.1%) 91 (42.3%) <0.001 
NYHA III or IV 501 (53.6%) 252 (71.6%) 296 (56.5%) 315 (73.9%) 158 (75.2%) <0.001 
LVEF (%)  30.26 ± 9.20 30.69 ± 11.48 31.51 ± 9.75 30.94 ± 12.11 34.04 ± 13.12 <0.001 
LVEF >40% 55 (5.7%) 34 (9.4%) 53 (9.9%) 51 (11.6%) 42 (19.4%) <0.001 
Ischemic HF 384 (39.8%) 172 (47.8%) 215 (40.3%) 231 (52.4%) 101 (46.8%) <0.001 
Previous HF hosp. 238 (24.7%) 154 (42.8%) 139 (26.0%) 187 (42.4%) 76 (35.2%) <0.001 
PCI/CABG 275 (28.5%) 133 (36.9%) 171 (32.0%) 174 (39.5%) 89 (41.2%) <0.001 
Atrial fibrillation 395 (40.9%) 183 (50.8%) 217 (40.6%) 230 (52.2%) 118 (54.6%) <0.001 
Stroke 69 (7.2%) 37 (10.3%) 46 (8.6%) 58 (13.2%) 23 (10.6%) 0.006 
Peripheral arterial disease 75 (7.8%) 34 (9.4%) 69 (12.9%) 68 (15.4%) 27 (12.5%) <0.001 
Device therapy 187 (19.4%) 113 (31.4%) 104 (19.5%) 149 (33.8%) 65 (30.1%) <0.001 
Hypertension 597 (61.9%) 234 (65.0%) 323 (60.5%) 275 (62.4%) 140 (64.8%) 0.64 
Diabetes 258 (26.7%) 151 (41.9%) 168 (31.5%) 162 (36.7%) 80 (37.0%) <0.001 
Smoking 138 (14.3%) 54 (15.0%) 82 (15.4%) 47 (10.7%) 32 (14.9%) 0.096 
COPD 134 (13.9%) 67 (18.6%) 78 (14.6%) 109 (24.7%) 48 (22.2%) <0.001 
Current malignancy 22 (2.3%) 18 (5.0%) 20 (3.7%) 20 (4.5%) 17 (7.9%) 0.001 
Hemoglobin, g/dL 13.57 ± 1.80 12.99 ± 1.71 13.45 ± 1.84 12.67 ± 1.91 12.35 ± 2.18 <0.001 
Anemia 164 (17.0%) 99 (27.5%) 115 (21.5%) 147 (33.3%) 92 (42.6%) <0.001 
eGFR, ml/min 68.91 ± 21.83 57.47 ± 22.62 65.56 ± 21.98 52.70 ± 23.78 54.05 ± 21.09 <0.001 
eGFR <60 345 (35.8%) 211 (58.6%) 219 (41.0%) 286 (64.9%) 144 (66.7%) <0.001 
Sodium, mmol/L 139.50 ± 3.62 138.88 ± 4.15 139.67 ± 3.56 138.16 ± 4.64 138.79 ± 4.53 <0.001 
Potassium, mmol/L 4.29 ± 0.57 4.24 ± 0.56 4.22 ± 0.49 4.28 ± 0.60 4.28 ± 0.61 0.18 
Glucose, mmol/L 6.95 ± 2.94 7.34 ± 3.21 7.09 ± 2.88 7.42 ± 3.30 7.36 ± 3.18 0.10 
NTproBNP, pg/mL 1912 (789, 4242) 3429 (1733, 7344) 2072.00 (1039, 4522) 4515 (2419, 10138) 4022 (1953, 7486) <0.001 
Beta-blocker 842 (87.3%) 293 (81.4%) 443 (83.0%) 349 (79.1%) 166 (76.9%) <0.001 
ACE/ARB 741 (76.8%) 243 (67.5%) 394 (73.8%) 294 (66.7%) 148 (68.5%) <0.001 
MRA 546 (56.6%) 204 (56.7%) 267 (50.0%) 227 (51.5%) 95 (44.0%) 0.003 
Legend:  BMI, body mass index; SBP, systolic blood pressure; NYHA, New York Heart Association; LVEF, left ventricular ejection fraction; PCI/CABG, 
percutaneous coronary intervention/coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular filtration 



























Supplemental Table 2. Competing-risk clinical models for the specific fatal events using continuous 
instead of categorical variables (BIOSTAT-CHF derivation) 
“Best” predictors SHR (95%CI) p-value 
Cardiovascular death 
SBP per 10 mmHg higher 0.94 (0.88-0.99) 0.027 
Per. Edema (yes) 1.51 (1.18-1.94) 0.001 
Ischemic HF (yes) 1.37 (1.09-1.71) 0.006 
Previous HF hosp. (yes) 1.30 (1.03-1.64) 0.028 
COPD (yes) 1.49 (1.16-1.91) 0.002 
eGFR per 10 ml/min higher 0.90 (0.85-0.95) <0.001 
NT-proBNP per log 1.39 (1.24-1.56) <0.001 
Troponin T per log 1.55 (1.28-1.87) <0.001 
Non-Cardiovascular death 
Age per 10 years older 1.34 (1.16-1.54) <0.001 
Anemia 1.83 (1.36-2.46) <0.001 




































Supplemental Table 3. Competing-risk clinical models for the hospitalization events (BIOSTAT-CHF 
derivation) 
“Best” predictors SHR (95%CI) p-value 
HF hospitalization 
NYHA III or IV 1.33 (1.03-1.73) 0.030 
Previous HF hosp. 1.42 (1.12-1.79) 0.003 
Diabetes 1.48 (1.18-1.85) 0.001 
Smoking 1.43 (1.01-2.03) 0.047 
eGFR ≤60 ml/min 1.33 (1.05-1.69) 0.020 
Log NT-proBNP, pg/mL 1.13 (1.03-1.23) 0.012 
Non-HF hospitalization 
Male 1.29 (1.01-1.65) 0.043 
HR, per 10bpm increase 1.07 (1.02-1.11) 0.004 
LVEF >40% 1.40 (1.00-1.95) 0.050 
Age, per 10yr increase 0.88 (0.81-0.96) 0.003 
Per. edema 0.76 (0.60-0.91) 0.004 
Log NT-proBNP, pg/mL 0.88 (0.81-0.95) 0.001 
Legend: HF, heart failure; eGFR, estimated glomerular filtration rate; LVEF, left ventricular ejection 
fraction; HR, heart rate. 
































Supplemental Table 4. Patients` characteristics by the combination of high CV risk and low non-CV 
risk vs. the rest of the BIOSTAT-CHF population   
Patients` characteristics Others High CV and low non-CV risk p-value 
N. 1996 520 
 
Age, years 69.41 ± 12.37 64.52 ± 9.28 <0.001 
Male 1414 (70.8%) 432 (83.1%) <0.001 
BMI, kg/m2 27.70 ± 5.37 28.60 ± 5.93 <0.001 
Heart rate, bpm 81.16 ± 20.97 86.70 ± 22.36 <0.001 
SBP, mmHg 125.84 ± 21.76 120.42 ± 21.93 <0.001 
Pulm. congestion/Rales 986 (51.0%) 305 (59.6%) <0.001 
Peripheral edema 890 (56.4%) 366 (70.4%) <0.001 
Orthopnea 653 (32.8%) 226 (43.5%) <0.001 
NYHA III or IV 1157 (59.8%) 365 (71.3%) <0.001 
LVEF (%)  31.79 ± 10.63 28.10 ± 9.90 <0.001 
LVEF >40% 205 (10.3%) 30 (5.8%) 0.002 
Ischemic HF 843 (42.2%) 260 (50.0%) 0.001 
Previous HF hosp. 602 (30.2%) 192 (36.9%) 0.003 
PCI/CABG 653 (32.7%) 189 (36.3%) 0.12 
Atrial fibrillation 903 (45.2%) 240 (46.2%) 0.71 
Stroke 174 (8.7%) 59 (11.3%) 0.065 
Peripheral arterial disease 210 (10.5%) 63 (12.1%) 0.30 
Device therapy 475 (23.8%) 143 (27.5%) 0.081 
Hypertension 1233 (61.8%) 336 (64.6%) 0.23 
Diabetes 616 (30.9%) 203 (39.0%) <0.001 
Smoking 249 (12.5%) 104 (20.0%) <0.001 
COPD 314 (15.7%) 122 (23.5%) <0.001 
Current malignancy 83 (4.2%) 14 (2.7%) 0.12 
Hemoglobin, g/dL 12.98 ± 1.94 13.96 ± 1.51 <0.001 
Anemia 598 (30.0%) 19 (3.7%) <0.001 
eGFR, ml/min 62.65 ± 23.55 61.68 ± 21.94 0.40 
eGFR <60 931 (46.6%) 274 (52.7%) 0.014 
Sodium, mmol/L 139.22 ± 3.98 138.85 ± 4.12 0.071 
Potassium, mmol/L 4.26 ± 0.55 4.28 ± 0.61 0.43 
Glucose, mmol/L 7.08 ± 3.01 7.41 ± 3.21 0.053 
NTproBNP, pg/mL 2366 (998, 5061) 3995 (2087, 7330) <0.001 
Troponin T, ng/mL 0.30 (0.20, 0.50) 0.50 (0.30-0.70) <0.001 
Beta-blocker 1670 (83.7%) 423 (81.3%) 0.21 
ACE/ARB 1441 (72.2%) 379 (72.9%) 0.75 
MRA 1005 (50.4%) 334 (64.2%) <0.001 
Legend:  BMI, body mass index; SBP, systolic blood pressure; NYHA, New York Heart Association; 
LVEF, left ventricular ejection fraction; PCI/CABG, percutaneous coronary intervention/coronary 
artery bypass grafting; COPD, chronic obstructive pulmonary disease; eGFR, estimated glomerular 
filtration rate; ACE/ARB, angiotensin converting enzyme/angiotensin receptor blockers; MRA, 
mineralocorticoid receptor antagonists.
 
Supplemental Table 5. Event-rate comparison between patients at high risk for CV death / low risk for non-CV death and rest of the study population. 
Subpopulations Total n. CV death n. (%) CV death Inc. Rate Non-CV death n. (%) Non-CV death Inc. Rate Ratio %  Diff. NNE 
Other 1996 328 (16.4) 9.7 (8.7-10.8) 175 (8.8) 5.2 (4.5-6.0) 1.9 4.5 22 
High CV / Low Non-CV risk  520 113 (21.7) 13.0 (10.8-15.7) 41 (7.9) 4.7 (3.5-6.4) 2.8 8.3 12 
Legend: CV, cardiovascular; Inc. Rate, incidence rate per 100 person-years; Ratio %, incidence rate ratio; Diff., incidence rate difference; NNE, number 
needed to enrol to have a cardiovascular death event (over a non-cardiovascular one). 
 
Supplemental Table 6. Competing-risk clinical models for the specific events in the validation cohort (n =1,738) 
“Best” predictors SHR (95%CI) p-value 
CV death (n =320) 
SBP <110 mmHg 1.39 (1.09-1.77) 0.008 
Per. edema 1.31 (1.03-1.66) 0.031 
Ischemic HF 1.16 (0.90-1.50) 0.24 
Previous HF hosp. 1.30 (1.03-1.67) 0.030 
COPD 1.09 (0.83-1.41) 0.56 
eGFR ≤60 ml/min 8.33 (1.92-33.3) 0.005 
NT-proBNP ≤1500, pg/mL Reference - 
>1500 & ≤5000 1.36 (1.01-1.84) 0.042 
>5000 2.08 (1.49-2.88) <0.001 
Troponin T ≤0.20, ng/mL Reference - 
>0.20 & ≤0.50 1.26 (0.87-1.82) 0.22 
>0.50 1.60 (1.06-2.42) 0.025 
Non-CV death (n =209) 
Age >75y 1.39 (1.03-1.86) 0.030 
Anemia 1.23 (0.93-1.64) 0.15 
NT-proBNP ≤1500, pg/mL Reference - 
>1500 & ≤5000 1.19 (0.87-1.64)  0.28 
>5000 1.09 (0.76-1.57) 0.63 
Legend: HF, heart failure; CV, cardiovascular; SBP, systolic blood pressure; eGFR, estimated glomerular filtration rate; 










Supplemental Table 7. Risk differentiation between CV and non-CV death in the validation cohort (n =1,738) 
CV death Risk Score (Quintiles) 
Points (from 0 to 13) Total n. CV death n. (%) CV death Inc. Rate Non-CV death n. (%) Non-CV death Inc. Rate Ratio %  Diff. NNE 
0-3 633 38 (6.0) 2.7 (1.9-3.7) 42 (6.6) 3.0 (2.2-4.0) 0.9 -0.3 345 
4-5 99 49 (49.4) 48.0 (35.8-62.7) 25 (25.2) 24.5 (16.1-35.4) 2.0 23.5 4 
6-7 405 65 (16.0) 8.0 (6.2-10.1) 48 (11.9) 5.9 (4.4-7.7) 1.3 2.1 48 
8-9 330 69 (20.9) 12.3 (9.6-15.4) 50 (15.2) 8.9 (6.7-11.6) 1.4 3.4 29 
10-13 271 99 (36.5) 24.1 (19.6-29.1) 44 (16.2) 10.7 (7.8-14.2) 2.3 13.4 7 
Non-CV death Risk Score (Quintiles) 
Points (from 0 to 6) Total n. CV death n. (%) CV death Inc. Rate Non-CV death n. (%) Non-CV death Inc. Rate Ratio % Diff. NNE 
0 130 10 (7.7) 3.4 (1.7-6.0) 14 (10.8) 4.8 (2.7-7.8) 0.7 -1.4 73 
1 78 19 (24.4) 13.7 (8.5-20.9) 15 (19.2) 10.9 (6.2-17.3) 1.3 2.9 35 
2 628 88 (14.0) 6.8 (5.4-8.3) 50 (8.0) 3.8 (2.9-5.0) 1.8 2.9 34 
3-4 680 138 (20.3) 11.3 (9.5-13.3) 97 (14.3) 7.9 (6.5-9.6) 1.4 3.4 30 
5-6 222 65 (29.3) 20.1 (15.6-25.3) 33 (14.9) 10.2 (7.1-14.1) 2.0 9.9 10 
Combined Risk Score (Quintiles) 
Points (from 0 to 15) Total n. CV death n. (%) CV death Inc. Rate Non-CV death n. (%) Non-CV death Inc. Rate Ratio % Diff. NNE 
0-4 399 22 (5.5) 2.5 (1.6-3.7) 24 (6.0) 2.7 (1.8-3.9) 0.9 -0.2 455 
5-6 267 110 (41.2) 32.0 (26.4-38.4) 50 (18.7) 14.6 (10.9-19.0) 2.2 17.4 6 
7-8 375 45 (12.0) 5.6 (4.2-7.5) 35 (9.3) 4.4 (3.1-6.0) 1.3 1.3 80 
9-10 379 67 (17.7) 9.2 (7.2-11.6) 48 (12.7) 6.6 (4.9-8.7) 1.4 2.6 38 
11-16 318 76 (23.9) 14.4 (11.4-17.9) 52 (16.4) 9.8 (7.4-12.7) 1.5 4.6 22 
Legend: CV, cardiovascular; Inc. Rate, incidence rate per 100 person-years; Ratio %, incidence rate ratio; Diff., incidence rate difference; NNE, number 
needed to enrol to have a cardiovascular death event (over a non-cardiovascular one). 
Supplemental Table 8. Criteria used for event adjudication.  
Cardiovascular 
ACS/ AMI 














































Supplemental Figure 2. CV death and non-CV death model calibration 
CV death: 
 
Non-CV death:  
 
The models were well calibrated: good overlap between observed and predicted events. 





Supplemental Figure 3. Unsupervised classification and regression trees (CART) for the studied 
events 
CV death: 
  
Non-CV death: 
